Clinical trial
A Single-arm, Open Label, Multi-center, Phase 2 Study of SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients Who Have Received Previous At Least Two Lines of Chemotherapy.
NCT03558191 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open Label, Multi-center, Phase 2 Study of SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients Who Have Received Previous At Least Two Lines of Chemotherapy.
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 14, 2018
- Completion date
- December 30, 2021
- Enrollment
- 156 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.